Variables | Hospital survivors n (%) or median (IQR) | Patients who did not complete the SF-36 form at 3 months n (%) or median (IQR) | Patients who completed the SF-36 form at 3 months n (%) or median (IQR) | p |
---|---|---|---|---|
N | 616 | 338 (55) | 278 (45) | |
Male | 252 (41) | 139 (41) | 113 (41) | 0.87 |
Age | 59 (47; 68) | 60 (47; 71) | 58 (47; 65) | 0.020 |
Performance status | ||||
0–2 | 529 (86) | 286 (85) | 243 (87) | |
3–4 | 85 (14) | 50 (15) | 35 (13) | |
Charlson index | 4 (2;5) | 4 (2; 6) | 4 (2; 5) | 0.024 |
Malignancies | 0.68 | |||
AML | 162 (26) | 82 (24) | 80 (29) | |
Non-Hodgkin’s lymphoma | 191 (31) | 111 (33) | 80 (29) | |
Hodgkin’s lymphoma | 18 (3) | 9 (3) | 9 (3) | |
ALL | 44 (7) | 22 (7) | 22 (8) | |
CLL | 45 (7) | 24 (7) | 21 (8) | |
CML | 14 (2) | 10 (3) | 4 (1) | |
Myeloma | 86 (14) | 51 (15) | 35 (13) | |
Myelodysplastic syndrome | 26 (4) | 14 (4) | 12 (4) | |
BMT/HSCT recipient | 0.024 | |||
Autologous | 78 (13) | 37 (11) | 41 (15) | |
Allogeneic | 70 (11) | 30 (9) | 40 (14) | |
Disease status at admission | 0.16 | |||
Newly diagnosed | 237 (41) | 135 (42) | 102 (39) | |
Partial remission | 46 (8) | 23 (7) | 23 (9) | |
Complete remission | 111 (19) | 52 (16) | 58 (23) | |
SOFA score | 5 (3; 7) | 5 (3; 7) | 5 (3; 7) | 0.67 |
Mechanical ventilation | 190 (31) | 111 (33) | 79 (28) | 0.22 |
Vasopressors | 219 (36) | 111 (33) | 100 (36) | 0.93 |
Renal replacement therapy | 106 (18) | 68 (21) | 38 (14) | 0.025 |
Sedation | 177 (29) | 100 (30) | 77 (28) | 0.59 |
ICU LOS (days) | 6 (3;10) | 6 (4; 10) | 5 (3; 10) | 0.24 |